Drug intelligence / Profile preview

Babysol

Development stage: Unknown
Lead developer: Qatar Pharma for Pharmaceutical Industries
Modality: Small Molecules
Administration: Oral

Overview

**Babysol** is a Qatar Pharma oral rehydration solution supplied in a 240 mL glass bottle. It is a fixed-combination electrolyte and carbohydrate preparation containing dextrose monohydrate, sodium chloride, trisodium citrate dihydrate, tripotassium citrate monohydrate, sodium metabisulfite, and citric acid monohydrate. The product is intended to restore fluids and electrolytes during dehydration, including dehydration associated with acute diarrhea, vomiting, or gastroenteritis. Glucose promotes intestinal sodium and water absorption through sodium-glucose cotransport, while sodium and potassium replenish key extracellular and intracellular electrolytes.

Brand names: Babysol
Other names: oral rehydration solutionORS

Targets

SLC5A1 (Sodium Glucose Cotransporter 1)

Beyond the preview

Go deeper on Babysol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Babysol.

Explore the full profile